Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
The funding round also saw participation from some of India's top angel investors and leading industry giants
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
Subscribe To Our Newsletter & Stay Updated